We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts. On April 23, 2026, Barclays lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $651 from $712 while maintaining an Overweight rating following the company’s Q1 results. The firm said the quarter delivered a “strong fundamental […]
Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on Rijnberk InvestInsights’s Substack by Daan | InvestInsights. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.’s share was trading at $451.29 as of April 21st. ISRG’s trailing and forward P/E were 59.16 and 46.51 […]
These longtime market beaters may not have peaked yet.
Intuitive Surgical recently reported past first-quarter 2026 results showing revenue of US$2,770.8 million and net income of US$821.5 million, alongside completing a multi-year buyback of 29,440,210 shares for US$9.08 billion. The combination of higher earnings per share and a reduced share count from the long-running repurchase program highlights management’s focus on reinforcing shareholder value through both operating performance and capital allocation. We’ll now examine how this stronger...
Robotic surgery’s market leader has had a rough start to 2026, but our model sees the pullback as an opportunity. Intuitive Surgical (NASDAQ:ISRG) trades at $482.22 after a 14.86% year-to-date decline, even as Q1 procedure growth and da Vinci 5 adoption continue to accelerate. Our 24/7 Wall St. price target for Intuitive Surgical is $615.93, ... Why Intuitive Surgical Is a Strong Buy as Robotic Surgery Adoption Accelerates
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical's strong Q1 results, rising procedures, and raised outlook highlight accelerating growth, while Boston Scientific faces headwinds and tempered guidance.